Skip to main content

Security report for junopharm.ca

Juno Pharmaceuticals Corp. · Healthcare · Canada

Medium risk. 6 critical or high findings in Email security, GDPR outside view and 1 other check.

Security score

69/100

Risk levelMedium

0–100, higher is better. How it is calculated

Juno Pharmaceuticals Corp. operates in the healthcare sector, specializing in licensing and acquiring specialized pharmaceutical products with limited competition and high market entry barriers. The company recently merged with Omega Laboratories Limited to form Juno Pharma Canada Inc, headquartered in Montreal, Quebec. The website serves as a corporate presence to inform stakeholders about the business and directs users to a new website for further engagement. Technically, the site is built on a modern CMS platform (Multiscreensite) and employs contemporary web technologies including service workers for PWA capabilities, Google Analytics, and Snowplow for analytics. However, it lacks visible privacy and cookie policies, and no contact information is provided on the homepage, which impacts user trust and compliance. Security posture is moderate with HTTPS enforced and captcha protections, but missing security headers and vulnerability disclosures reduce overall security maturity. The absence of WHOIS data raises concerns about domain legitimacy, although the website content appears professional and business-focused.

Scanned

NIS2 and GDPR posture

GDPR outside view
35/ 100 · High
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

6 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Privacy Policy found

      GDPR requires a clear and accessible privacy policy

      What to do: Add a comprehensive privacy policy page and link to it prominently

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

    • High

      Third-party services without privacy policy

      Detected services: Google Analytics

      What to do: Document all third-party data sharing in your privacy policy

Need hands-on remediation? Email guard@offseq.com

Keep watching junopharm.ca

This scan found 22 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
70
Email security
60
DNS health
75
Network security
100
GDPR outside view
35
Average
69

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Juno Pharmaceuticals holds a niche position in the pharmaceutical licensing and acquisition market in Canada, targeting healthcare professionals and industry stakeholders. The business model focuses on acquiring specialized products with inherent market barriers, suggesting a strategy to maintain competitive advantage through exclusivity. The recent merger indicates growth and consolidation. The website acts primarily as a corporate informational portal with limited direct customer interaction. The lack of detailed contact information and policies suggests a low emphasis on direct consumer engagement or e-commerce. The presence of a related domain (junopharma.com) indicates a transition or expansion of their digital footprint. Overall, the company appears to be a small-sized entity with focused operations in healthcare licensing.

Security posture

The website demonstrates a basic to moderate security posture. HTTPS is properly implemented, and service workers are registered to enhance performance and offline capabilities. The use of Google reCAPTCHA and Friendly Captcha indicates attention to bot mitigation on forms, although no forms are present on the homepage. The absence of explicit security headers such as Content-Security-Policy, X-Frame-Options, and others is a notable gap. No vulnerability disclosures or incident response contacts are provided, limiting transparency and readiness for security incidents. The missing WHOIS data is a significant concern for domain legitimacy and trust. Overall, while the site is not evidently vulnerable, there are areas for improvement in security best practices and compliance documentation.

Recommendations

  1. Publish comprehensive privacy and cookie policies to improve compliance and user trust.
  2. Add explicit security headers to enhance protection against common web attacks.
  3. Provide clear contact information including security incident contacts and business communication channels.
  4. Register and publish a vulnerability disclosure policy or security.txt file to demonstrate security transparency.
  5. Investigate and resolve the missing WHOIS data issue to improve domain legitimacy and trustworthiness.

Contact details published on the site

Addresses
Legal name
Juno Pharmaceuticals Corp.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Juno Pharmaceuticals Corp.
Description
Juno licenses and acquires specialized pharmaceutical products that have limited competitors and inherent barriers to market entry.
Key services
Licensing pharmaceutical products, Acquisition of pharmaceutical products
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.7.0, Google Analytics, Google Tag Manager, Snowplow Analytics, Service Worker, Mapbox, reCAPTCHA, Friendly Captcha, PhotoSwipe
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
80/100
Good practices seen
  • HTTPS enforced
  • Service Worker registered
  • Use of reCAPTCHA and Friendly Captcha for forms

Analytics and tracking

Services
Google Analytics, Snowplow Analytics
Tracking level
moderate
Privacy practices
poor

Advertising

Tracking pixels
Snowplow Analytics
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
moderate

Key observations

  1. Website is accessible and not blocked by WAF or security mechanisms.
  2. No privacy policy, cookie policy, or terms of service pages detected.
  3. No contact emails, phone numbers, or physical addresses found on the homepage.
  4. Website uses modern JavaScript libraries and analytics tools.
  5. No forms detected on the homepage for data collection.
  6. Website content is focused on pharmaceutical licensing and acquisitions.
  7. WHOIS data is missing, indicating possible unregistered domain or privacy protection.
  8. No explicit security headers detected in the HTML content.
  9. Site uses HTTPS and service workers for PWA capabilities.
  10. No vulnerability disclosure or security.txt found.
Technical notes

Notes

The website is built on the Multiscreensite platform using a modern tech stack including jQuery 3.7.0, Google Analytics, Google Tag Manager, and Snowplow for analytics. It employs service workers for PWA functionality and uses Mapbox for mapping services. The site loads CSS and JS asynchronously for performance optimization. The design is responsive and mobile-friendly with good SEO meta tags and Open Graph data. However, the site lacks advanced accessibility features and explicit security headers. The hosting appears to be via a CDN provided by the CMS vendor, ensuring reasonable performance. No forms or interactive data collection elements are present on the homepage, reducing attack surface but also limiting user engagement. Overall, the technical implementation is solid but could benefit from enhanced security and compliance features.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with junopharm.ca. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review junopharm.ca.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.